Drug Profile
Meloxicam - Boehringer Ingelheim
Alternative Names: Amelotex; Mobec; Mobic; Mobicox; Movalis; Movatec; Parocin; Tenaron; UH AC 62; UH AC 62 XX; UH AE 62 XX; UticoxLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class 2 ring heterocyclic compounds; Amides; Analgesics; Anti-inflammatories; Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Small molecules; Thiazines; Thiazoles
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Ankylosing spondylitis; Back pain; Gout; Juvenile rheumatoid arthritis; Neuropathic pain; Osteoarthritis; Periarthritis; Rheumatoid arthritis
- Discontinued Preterm labour
Most Recent Events
- 06 Nov 2018 Boehringer Ingelheim completes a phase I trial in Healthy volunteers in Russia (PO) (NCT03684265)
- 05 Oct 2018 Boehringer Ingelheim initiates enrolment in a phase I bioavailability and bioequivalence trial in healthy volunteers in Russia (PO, Capsule) (NCT03684265)
- 25 Sep 2018 Boehringer Ingelheim plans a phase I bioavailability study in Healthy volunteers (PO) (NCT03684265)